{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:01:13Z","timestamp":1787061673110,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Increasingly widespread use of programmed cell death protein 1 (PD-1) immune checkpoint inhibitors (ICIs) for treatment of a variety of progressive malignancies continues to reveal a range of immune-related adverse events (irAEs), necessitating immunosuppressive therapy for management. While a single course of systemic corticosteroids may be sufficient for many irAEs, no clear standard-of-care guidelines exist for steroid-refractory cases. We present an unusual case of a patient who developed several steroid-refractory novel irAEs on pembrolizumab despite ongoing B cell-directed immunosuppressive therapy with rituximab, who ultimately noted resolution of symptoms with tacrolimus, a T-cell-directed immunosuppressant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>This 72-year-old Caucasian man with Waldenstrom\u2019s macroglobulinemia and myelin-associated glycoprotein (MAG) immunoglobulin M (IgM) antibody-associated neuropathy was being treated with maintenance rituximab and intravenous immunoglobulin when he was started on pembrolizumab (2.26 mg\/kg) for metastatic urothelial cancer 31 months after surgery and adjuvant chemotherapy. After his third dose of pembrolizumab, he developed a painful blistering papular rash of the distal extremities. He received two more doses of pembrolizumab before he also developed diarrhea, and it was held; he was initiated on 1\u00a0mg\/kg prednisone for presumed ICI-induced dermatitis and colitis. Skin biopsy 10\u00a0weeks after cessation of pembrolizumab and taper of steroids to 20\u00a0\u00a0mg daily revealed a unique bullous erythema multiforme. He was then admitted with dyspnea and imaging concerning for necrotizing pneumonia, but did not respond to antibiotic therapy. Bronchoscopy and biopsy revealed acute fibrinous organizing pneumonia. His symptoms failed to fully respond to multiple courses of high-dose systemic corticosteroids and a trial of azathioprine, but pneumonia, diarrhea, and skin rash all improved markedly with tacrolimus. The patient has since completed his therapy for tacrolimus, continues off of ICI, and has not experienced a recurrence of any irAEs, though has more recently experienced progression of his cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite immunosuppression with rituximab and intravenous immunoglobulin, two immunomodulators targeting B cells, ICI cessation, and systemic corticosteroid therapy, our patient developed two high-grade unusual irAEs, bullous erythema multiforme and acute fibrinous organizing pneumonia. Our patient\u2019s improvement with tacrolimus can offer critical insight into the pathophysiology of steroid-refractory irAEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-021-02670-3","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T20:18:21Z","timestamp":1616098701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report"],"prefix":"10.1186","volume":"15","author":[{"given":"Jacobi","family":"Hines","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0498-3118","authenticated-orcid":false,"given":"Ellen","family":"Daily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh Khoa","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urooba","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya N.","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter M.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankti","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"issue":"12","key":"2670_CR1","first-page":"e3700","volume":"10","author":"S Sahni","year":"2018","unstructured":"Sahni S, Valecha G, Sahni A. Role of anti-PD-1 antibodies in advanced melanoma: the era of immunotherapy. Cureus. 2018;10(12):e3700.","journal-title":"Cureus."},{"key":"2670_CR2","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"I Ribas","year":"2015","unstructured":"Ribas I, Puzanov RD, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908\u201318.","journal-title":"Lancet Oncol."},{"issue":"15","key":"2670_CR3","doi-asserted-by":"publisher","first-page":"S4531","DOI":"10.1200\/JCO.2019.37.15_suppl.4531","volume":"37","author":"R Morales-Barera","year":"2019","unstructured":"Morales-Barera R, Rodriguez CS, Gonzalez M, Ros J, Semidey ME, Hernandez ES, et al. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Clin Oncol. 2019;37(15):S4531.","journal-title":"J Clin Oncol."},{"key":"2670_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","volume":"79","author":"TJ Braaten","year":"2020","unstructured":"Braaten TJ, Brahmer JR, Forde PM, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2020;79:332\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2670_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1634\/theoncologist.2018-0352","volume":"24","author":"N Asher","year":"2019","unstructured":"Asher N, Marom EM, Ben-Betzalel G, Baruch EN, Steinberg-Silman Y, Schachter J, Shapira-Frommer R, Markel G. Recurrent pneumonitis in patients with melanoma treated with immune checkpoint inhibitors. Oncologist. 2019;24(5):640\u20137.","journal-title":"Oncologist"},{"key":"2670_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1159\/000494841","volume":"63","author":"C Jong","year":"2018","unstructured":"Jong C, Peters B, Schramel F, et al. Recurrent episodes of nivolumab induced pneumonitis after nivolumab discontinuation and the time course of carcinoembryonic antigen levels: a case of a 58-year-old woman with non-small cell lung cancer. Chemotherapy. 2018;63:272\u20137.","journal-title":"Chemotherapy."},{"key":"2670_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","volume":"10","author":"L Marthey","year":"2016","unstructured":"Marthey L, Mateus C, Mussini C, et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis. 2016;10:395\u2013401.","journal-title":"J Crohns Colitis."},{"issue":"1","key":"2670_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/25785826.2019.1580477","volume":"42","author":"H Kikuchi","year":"2019","unstructured":"Kikuchi H, Sakuraba H, Akemoto Y, Murai Y, Fukutoku Y, Asari T, Tatsuta T, Hasui K, Hiraga H, Sawaya M, Chinda D, Mikami T, Tanaka M, Fukuda S. A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine. Immunol Med. 2019;42(1):39\u201344.","journal-title":"Immunol Med"},{"issue":"5","key":"2670_CR9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/PAS.0000000000000829","volume":"41","author":"JH Chen","year":"2017","unstructured":"Chen JH, Pezhouh MK, Lauwers GY, Masia R. Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol. 2017;41(5):643\u201354.","journal-title":"Am J Surg Pathol."},{"key":"2670_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","volume":"6","author":"DH Johnson","year":"2018","unstructured":"Johnson DH, Zobniw CM, Trinh VA, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immuno Therapy Cancer. 2018;6:103.","journal-title":"J Immuno Therapy Cancer."},{"issue":"6","key":"2670_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1212\/WNL.0000000000007380","volume":"93","author":"M Touat","year":"2019","unstructured":"Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology. 2019;93(6):280.","journal-title":"Neurology."},{"issue":"5","key":"2670_CR12","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1177\/1078155218793709","volume":"25","author":"T Beardslee","year":"2019","unstructured":"Beardslee T, Draper A, Kudchadkar R. Tacrolimus for the treatment of immune related adverse effects refractory to systemic steroids and anti-tumor necrosis factor \u03b1 therapy. J Oncol Pharm Pract. 2019;25(5):1275\u2013981.","journal-title":"J Oncol Pharm Pract"},{"key":"2670_CR13","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomized, controlled, phase 2 trial. Lancet Oncol. 2015;16:908\u201318.","journal-title":"Lancet Oncol"},{"key":"2670_CR14","first-page":"95","volume":"20","author":"R Kuint","year":"2017","unstructured":"Kuint R, Lotem M, Neuman T, Bekker-Milovanov E, Abutbul A, Laxer U, Berkman N, Fridlender ZG. Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma\u2014a case report. Respir Med Case Rep. 2017;20:95\u20137.","journal-title":"Respir Med Case Rep"},{"issue":"8","key":"2670_CR15","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/cup.12717","volume":"43","author":"G Jour","year":"2016","unstructured":"Jour G, Glitza IC, Ellis RM, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol. 2016;43(8):688\u201396.","journal-title":"J Cutan Pathol"},{"issue":"9","key":"2670_CR16","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","volume":"154","author":"L Wang","year":"2018","unstructured":"Wang L, Patel G, Chiesa-Fuxench Z, et al. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol. 2018;154(9):1057\u201361.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"2670_CR17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/cup.12717","volume":"43","author":"G Jour","year":"2016","unstructured":"Jour G, et al. Autoimmune dermatologic toxicities from autoimmune checkpoint inhibitor blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol. 2016;43(8):688\u201396.","journal-title":"J Cutan Pathol."},{"key":"2670_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/ITT.S126227","volume":"6","author":"JM Yoest","year":"2017","unstructured":"Yoest JM. Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. Immunotargets Ther. 2017;6:73\u201382.","journal-title":"Immunotargets Ther."},{"issue":"17","key":"2670_CR19","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714\u201368.","journal-title":"J Clin Oncol."},{"issue":"1","key":"2670_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95.","journal-title":"J Immunother Cancer."}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02670-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-021-02670-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02670-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T20:33:09Z","timestamp":1616099589000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-02670-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2670"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-02670-3","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"22 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors obtained the patient\u2019s consent to participate as below; no additional participation was required beyond his standard ongoing medical care.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}